In this 9 minute video from day 2 of Rebellion in EM 2021, I go over the evidence for advanced imaging use in acute ischemic stroke of unknown time of onset to help guide treatment with intravenous alteplase.
Background: The mainstays for management of stroke include admission to a stroke center and management of modifiable risk factors.1,2,3 It is estimated that most strokes are ischemic (87%),4 and atrial fibrillation and/or flutter are thought to be responsible for approximately ...
Background: Acute basilary artery occlusion has a high morbidity and mortality. Treatment strategies for acute basilar artery occlusion are rather sparse. Endovascular research over the last 5 years (REBEL EM Post) adds little to the conversation of these strokes as ...
Background: Alteplase has been the accepted thrombolytic for acute ischemic stroke (AIS) for 25 years. However, recent data has emerged regarding tenectaplase as an alternative. Tenecteplase is a modified form of alteplase, with a lower cost and more favorable pharmacokinetic ...
Background: Intravenous alteplase is the current standard care for treatment of acute ischemic stroke (AIS) despite active debate on the research supporting its use. The window for its use has been restricted to <3h of symptom onset based on the ...
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
